Tumour necrosis factor-alpha and tuberculosis: guidance from the National TB Advisory Committee.
Kavanagh
P M
PM
paul.kavanagh@hse.ie
Gilmartin
J J
JJ
O'Donnell
J
J
O'Flanagan
D
D
D000068879:Adalimumab; D026683:Advisory Committees; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D019072:Antibiotic Prophylaxis; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D000995:Antitubercular Agents / Q000008:administration & dosage*; D000068800:Etanercept; D006801:Humans; D007154:Immune System Diseases / Q000209:etiology; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000009:adverse effects; D000069285:Infliximab; D007494:Ireland; D017410:Practice Guidelines as Topic; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage; D014376:Tuberculosis / Q000188:drug therapy / Q000209:etiology* / Q000517:prevention & control; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000502:physiology*
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D000995:Antitubercular Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept